Literature DB >> 17709528

Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection.

Marjon Navis1, Ingrid Schellens, Debbie van Baarle, José Borghans, Peter van Swieten, Frank Miedema, Neeltje Kootstra, Hanneke Schuitemaker.   

Abstract

HLA B57 and the closely related HLA B5801 are over-represented among HIV-1 infected long-term nonprogressors (LTNPs). It has been suggested that this association between HLA B57/5801 and asymptomatic survival is a consequence of strong CTL responses against epitopes in the viral Gag protein. Moreover, CTL escape mutations in Gag would coincide with viral attenuation, resulting in low viral load despite evasion from immune control. In this study we compared HLA B57/5801 HIV-1 infected progressors and LTNPs for sequence variation in four dominant epitopes in Gag and their ability to generate CTL responses against these epitopes and the autologous escape variants. Prevalence and appearance of escape mutations in Gag epitopes and potential compensatory mutations were similar in HLA B57/5801 LTNPs and progressors. Both groups were also indistinguishable in the magnitude of CD8+ IFN-gamma responses directed against the wild-type or autologous escape mutant Gag epitopes in IFN-gamma ELISPOT analysis. Interestingly, HIV-1 variants from HLA B57/5801 LTNPs had much lower replication capacity than the viruses from HLA B57/5801 progressors, which did not correlate with specific mutations in Gag. In conclusion, the different clinical course of HLA B57/5801 LTNPs and progressors was not associated with differences in CTL escape mutations or CTL activity against epitopes in Gag but rather with differences in HIV-1 replication capacity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709528     DOI: 10.4049/jimmunol.179.5.3133

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Correlates of spontaneous viral control among long-term survivors of perinatal HIV-1 infection expressing human leukocyte antigen-B57.

Authors:  Yanhua Tang; Sihong Huang; Jacqueline Dunkley-Thompson; Julianne C Steel-Duncan; Elizabeth G Ryland; M Anne St John; Rohan Hazra; Celia D C Christie; Margaret E Feeney
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Comprehensive analysis of unique cases with extraordinary control over HIV replication.

Authors:  Daniel Mendoza; Sarah A Johnson; Bennett A Peterson; Ven Natarajan; Maria Salgado; Robin L Dewar; Peter D Burbelo; Nicole A Doria-Rose; Erin H Graf; Jamieson H Greenwald; Jessica N Hodge; William L Thompson; Nancy A Cogliano; Cheryl L Chairez; Catherine A Rehm; Sara Jones; Claire W Hallahan; Joseph A Kovacs; Irini Sereti; Omar Sued; Sheila A Peel; Robert J O'Connell; Una O'Doherty; Tae-Wook Chun; Mark Connors; Stephen A Migueles
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

3.  Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B*17-positive simian immunodeficiency virus-infected rhesus macaques.

Authors:  Nicholas J Maness; Levi J Yant; Chungwon Chung; John T Loffredo; Thomas C Friedrich; Shari M Piaskowski; Jessica Furlott; Gemma E May; Taeko Soma; Enrique J León; Nancy A Wilson; Helen Piontkivska; Austin L Hughes; John Sidney; Alessandro Sette; David I Watkins
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

4.  Clade-specific evolution mediated by HLA-B*57/5801 in human immunodeficiency virus type 1 clade A1 p24.

Authors:  Lyle R McKinnon; Rupert Capina; Harold Peters; Mark Mendoza; Joshua Kimani; Charles Wachihi; Anthony Kariri; Makobu Kimani; Meika Richmond; Sandy Koesters Kiazyk; Keith R Fowke; Walter Jaoko; Ma Luo; T Blake Ball; Francis A Plummer
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

5.  HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia.

Authors:  Christine M Durand; Karen A O'Connell; Linda G Apuzzo; Susan J Langan; Hejab Imteyaz; Aima A Ahonkhai; Christina M Ceccato; Thomas M Williams; Joseph B Margolick; Joel N Blankson
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

6.  Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection.

Authors:  Leia H Wren; Amy W Chung; Gamze Isitman; Anthony D Kelleher; Matthew S Parsons; Janaki Amin; David A Cooper; Ivan Stratov; Marjon Navis; Stephen J Kent
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

7.  Early HLA-B*57-restricted CD8+ T lymphocyte responses predict HIV-1 disease progression.

Authors:  Catherine A Brennan; F Javier Ibarrondo; Catherine A Sugar; Mary Ann Hausner; Roger Shih; Hwee L Ng; Roger Detels; Joseph B Margolick; Charles R Rinaldo; John Phair; Lisa P Jacobson; Otto O Yang; Beth D Jamieson
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

8.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Maternal transmission of human immunodeficiency virus escape mutations subverts HLA-B57 immunodominance but facilitates viral control in the haploidentical infant.

Authors:  Arne Schneidewind; Yanhua Tang; Mark A Brockman; Elizabeth G Ryland; Jacqueline Dunkley-Thompson; Julianne C Steel-Duncan; M Anne St John; Joseph A Conrad; Spyros A Kalams; Francine Noel; Todd M Allen; Celia D Christie; Margaret E Feeney
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

10.  Epitope discovery with phylogenetic hidden Markov models.

Authors:  Miguel Lacerda; Konrad Scheffler; Cathal Seoighe
Journal:  Mol Biol Evol       Date:  2010-01-20       Impact factor: 16.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.